-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LBIQrn+N9kURQRduip/amnJgeYnUryc8Llaqp4Zl0cHd5RenXuPHkHQQiuC3cNZK lX+vbXdl+baqwdIxzIqPNA== 0000950144-07-003540.txt : 20070419 0000950144-07-003540.hdr.sgml : 20070419 20070418174549 ACCESSION NUMBER: 0000950144-07-003540 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070416 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20070419 DATE AS OF CHANGE: 20070418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATHEROGENICS INC CENTRAL INDEX KEY: 0001107601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 582108232 STATE OF INCORPORATION: GA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-31261 FILM NUMBER: 07774394 BUSINESS ADDRESS: STREET 1: 8995 WESTSIDE PARKWAY CITY: ALPHARETTA STATE: GA ZIP: 30004 BUSINESS PHONE: 6783362500 8-K 1 g06782e8vk.htm ATHEROGENICS, INC. ATHEROGENICS, INC.
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 16, 2007
ATHEROGENICS, INC.
(Exact Name of Registrant as Specified in its Charter)
         
Georgia   0-31261   58-2108232
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (I.R.S. Employer
Identification Number)
8995 Westside Parkway
Alpharetta, GA 30004
(Address of principal executive offices)
Registrant’s telephone number, including area code (678) 336-2500
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e)      We announced the full results of the ARISE clinical trial on March 27, 2007. In connection with these results, the Compensation Committee of our Board of Directors approved the following cash bonus payments, which represent 63% of their target bonus, to the executive officers listed below.
             
Name   Title   Bonus Amount
Mark P. Colonnese
   Executive Vice President,   $ 59,724  
 
   Commercial Operations and        
 
   Chief Financial Officer        
 
            
Robert A.D. Scott, M.D.
   Executive Vice President,   $ 59,724  
 
   Research & Development and        
 
   Chief Medical Officer        
 
            
Joseph M. Gaynor, Jr.
   Senior Vice President,   $ 48,510  
 
   General Counsel and        
 
   Corporate Secretary        
 
            
W. Charles Montgomery, Ph.D.
   Senior Vice President,   $ 50,274  
 
   Business Development &        
 
   Alliance Management        
In addition, a special bonus of $40,276 was awarded to Dr. Scott for successfully conducting the ARISE clinical trial.

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
         
  ATHEROGENICS, INC.
 		  
Date: April 18, 2007  /s/ MARK P. COLONNESE    
  Mark P. Colonnese    
  Executive Vice President, Commercial Operations and Chief Financial Officer   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----